A5027649822- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Coronary Interventions and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Lipoproteins and Cardiovascular Health
- Cardiac Imaging and Diagnostics
- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac Valve Diseases and Treatments
- Vascular Procedures and Complications
- Cardiac Arrhythmias and Treatments
- Cardiomyopathy and Myosin Studies
- Health Systems, Economic Evaluations, Quality of Life
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer, Lipids, and Metabolism
- Pharmaceutical Economics and Policy
- Peripheral Artery Disease Management
- Cardiovascular Effects of Exercise
- Pharmacology and Obesity Treatment
- Central Venous Catheters and Hemodialysis
- Metabolism, Diabetes, and Cancer
- Atherosclerosis and Cardiovascular Diseases
- Platelet Disorders and Treatments
University of Campania "Luigi Vanvitelli"
2016-2025
Ospedale Sant'Anna
2019-2025
Ospedale Monaldi
2016-2025
I.R.C.C.S. Oasi Maria SS
2018-2024
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2024
IRCCS Ospedale San Raffaele
2024
University Hospital of Bern
2018-2022
University of Bern
2018-2022
Fudan University Shanghai Cancer Center
2020
University of Zurich
2020
Aims: The Academic Research Consortium for High Bleeding Risk (ARC-HBR) defined consensus-based criteria patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI). We aimed to validate the ARC-HBR outcomes using a large cohort of PCI. Methods and results: Between 2009 2016, PCI were prospectively included in Bern Registry. Patients considered be HBR if least one major criterion or two minor met. primary endpoint was (BARC) 3 5 year; ischaemic assessed...
Abstract Background The inflammatory response occurring in acute myocardial infarction (AMI) has been proposed as a potential pharmacological target. Sodium-glucose co-transporter 2 inhibitors (SGLT2-I) currently receive intense clinical interest patients with and without diabetes mellitus (DM) for their pleiotropic beneficial effects. We tested the hypothesis that SGLT2-I have anti-inflammatory effects along glucose-lowering properties. Therefore, we investigated link between stress...
To investigate in-hospital and long-term prognosis in T2DM patients presenting with acute myocardial infarction (AMI) treated SGLT2-I versus other oral anti-diabetic agents (non-SGLT2-I users).
To validate the set of clinical and biochemical criteria proposed by consensus Academic Research Consortium (ARC) for High Bleeding Risk (HBR) identification HBR patients. These were categorized into major minor, if expected to carry in isolation, respectively, ≥4% <4% (BARC) 3 or 5 bleeding risk within 1-year after percutaneous coronary intervention (PCI). patients are those meeting at least 1 2 minor criteria.All undergoing PCI Bern University Hospital, between February 2009 September 2018...
In patients with Normal Glucose Tolerance (NGT) some causes of ischemic heart disease (IHD) were not completely investigated. The role both metabolic milieu and adipokines in IHD progression was fully Our aim to assess the link between plasma levels, insulin resistance (IR) NGT undergoing Percutaneous Coronary Intervention (PCI). AIRE is a single-center prospective longitudinal observational study investigating outcome subjects who underwent coronary revascularization by PCI third level...
Background: Standard administration of newer oral P2Y 12 inhibitors, including prasugrel or ticagrelor, provides suboptimal early inhibition platelet aggregation (IPA) in patients with ST-segment–elevation myocardial infarction undergoing primary percutaneous coronary intervention. We aimed to investigate the effects cangrelor, tirofiban, and prasugrel, administered as chewed integral loading dose, on IPA Methods: The FABOLUS-FASTER trial (Facilitation Through Aggrastat Cangrelor Bolus...
Sodium-glucose co-transporter 2 inhibitors (SGLT2-i) have shown significant cardiovascular benefits in patients with and without type diabetes mellitus (T2DM). They also gained interest for their potential anti-arrhythmic role ability to reduce the occurrence of atrial fibrillation (AF) ventricular arrhythmias (VAs) T2DM heart failure patients.To investigate in-hospital new-onset cardiac a cohort presenting acute myocardial infarction (AMI) treated SGLT2-i vs. other oral anti-diabetic agents...
A substantial number of patients with severe aortic stenosis (AS) undergoing transcatheter valve implantation (TAVI) experience adverse events after TAVI, health care expenditure. We aimed to investigate cardiac remodeling and long-term outcomes in diabetic AS, left ventricular ejection fraction (LVEF) < 50%, extra-valvular damage (EVCD) TAVI treated sodium-glucose cotransporter-2 inhibitors (SGLT2i) versus other glucose-lowering strategies (no-SGLT2i users). Multicenter international...